Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

SALAJ, Peter, Petra OVESNÁ, Miroslav PENKA and Ulla HEDNER. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia. 2012, vol. 18, No 6, p. e409-e411, 3 pp. ISSN 1351-8216. Available from: https://dx.doi.org/10.1111/j.1365-2516.2012.02920.x.

Basic information

• Original name: Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
• Authors: SALAJ, Peter (203 Czech Republic, guarantor), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Miroslav PENKA (203 Czech Republic) and Ulla HEDNER (752 Sweden).
• Edition: Haemophilia, 2012, 1351-8216.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 3.170
• RIV identification code: RIV/00216224:14110/12:00062520
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1111/j.1365-2516.2012.02920.x
• UT WoS: 000310553600006
• Keywords in English: bleeding disorders; inhibitor

Abstract

Haemophilia registries, such as HemoRec, provide a valuable source of real-world data for the study of treatment modalities. We have reported that early treatment with rFVIIa appeared more effective than delayed-onset treatment in controlling the incidence of re-bleeding. The current study investigated whether time to treatment and/or initial dose of rFVIIa affects bleeding duration and, for the first time, their impact on acute pain control in inhibitor patients.